{"pmid":32359182,"title":"Occurrence of SARS-CoV-2 during mycophenolate mofetil treatment for pemphigus.","text":["Occurrence of SARS-CoV-2 during mycophenolate mofetil treatment for pemphigus.","we read with great interest the article entitled \"Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases?\" published by Di Altobrando A. et al. in the JEADV. This is the first report of COronaVIrus DIsease 2019 (COVID-19) in a patient affected by autoimmune blistering disease (ABD) during immunosuppressive treatment (i.e. azathioprine). The authors conclude that it is crucial to learn of more cases of ABD patients under immunosuppressive treatment who have developed COVID-19, in order to better quantify the risk of infection under immunosuppressive therapy.","J Eur Acad Dermatol Venereol","Balestri, R","Rech, G","Girardelli, C R","32359182"],"abstract":["we read with great interest the article entitled \"Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases?\" published by Di Altobrando A. et al. in the JEADV. This is the first report of COronaVIrus DIsease 2019 (COVID-19) in a patient affected by autoimmune blistering disease (ABD) during immunosuppressive treatment (i.e. azathioprine). The authors conclude that it is crucial to learn of more cases of ABD patients under immunosuppressive treatment who have developed COVID-19, in order to better quantify the risk of infection under immunosuppressive therapy."],"journal":"J Eur Acad Dermatol Venereol","authors":["Balestri, R","Rech, G","Girardelli, C R"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32359182","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/jdv.16578","keywords":["covid-19","sars-cov-2","blistering disorders","bullous disorders","immunosuppressive therapy","mycophenolate mofetil"],"e_drugs":["Mycophenolic Acid","Azathioprine"],"topics":["Case Report"],"weight":1,"_version_":1666138495297519619,"score":9.490897,"similar":[{"pmid":32302437,"title":"Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases?","text":["Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases?","In this dramatic period where the whole world is affected by the outbreak of coronavirus disease 19 (COVID-19), scientific data relating to the causative virus SARS-CoV-2 as well as the subsequent therapeutic repercussions on the management of other diseases should be divulged in order to share as much information as possible among experts in a timely manner.","J Eur Acad Dermatol Venereol","Di Altobrando, Ambra","Patrizi, Annalisa","Bardazzi, Federico","32302437"],"abstract":["In this dramatic period where the whole world is affected by the outbreak of coronavirus disease 19 (COVID-19), scientific data relating to the causative virus SARS-CoV-2 as well as the subsequent therapeutic repercussions on the management of other diseases should be divulged in order to share as much information as possible among experts in a timely manner."],"journal":"J Eur Acad Dermatol Venereol","authors":["Di Altobrando, Ambra","Patrizi, Annalisa","Bardazzi, Federico"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302437","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jdv.16491","keywords":["covid-19","sars-cov-2","blistering disorders","bullous disorders","immunosuppressive therapy"],"topics":["Treatment"],"weight":1,"_version_":1666138494763794432,"score":198.22119},{"pmid":32333823,"title":"Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic.","text":["Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic.","Autoimmune bullous diseases (AIBDs) are potentially life-threatening disorders comprising intra-epidermal/epithelial (pemphigus) and sub-epidermal/epithelial blistering diseases (pemphigoid and dermatitis herpetiformis). Corticosteroids and non-steroid immunomodulatory agents are the mainstays of treatment. Treatment can be challenging particularly in pemphigus, mucous membrane pemphigoid, and epidermolysis bullosa acquisita which may require more intense immunosuppressive approaches.","J Eur Acad Dermatol Venereol","Kasperkiewicz, M","Schmidt, E","Fairley, J A","Joly, P","Payne, A S","Yale, M L","Zillikens, D","Woodley, D T","32333823"],"abstract":["Autoimmune bullous diseases (AIBDs) are potentially life-threatening disorders comprising intra-epidermal/epithelial (pemphigus) and sub-epidermal/epithelial blistering diseases (pemphigoid and dermatitis herpetiformis). Corticosteroids and non-steroid immunomodulatory agents are the mainstays of treatment. Treatment can be challenging particularly in pemphigus, mucous membrane pemphigoid, and epidermolysis bullosa acquisita which may require more intense immunosuppressive approaches."],"journal":"J Eur Acad Dermatol Venereol","authors":["Kasperkiewicz, M","Schmidt, E","Fairley, J A","Joly, P","Payne, A S","Yale, M L","Zillikens, D","Woodley, D T"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333823","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/jdv.16525","keywords":["covid-19","sars-cov-2","pemphigoid","pemphigus"],"e_drugs":["Steroids"],"topics":["Prevention"],"weight":1,"_version_":1666138494048665600,"score":193.37698},{"pmid":32358791,"title":"SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor.","text":["SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor.","we read with great interest the article entitled \"SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor\" published by Messina F. and Piaserico S. in the JEADV.(1) This is the first report of COronaVIrus DIsease 2019 (COVID-19) in a psoriatic patient treated with a biologic. Whilst the authors reported an infection that occurred during therapy with an IL-23 inhibitor, we would like to briefly report one that occurred during therapy with an IL-17 inhibitor.","J Eur Acad Dermatol Venereol","Balestri, R","Rech, G","Girardelli, C R","32358791"],"abstract":["we read with great interest the article entitled \"SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor\" published by Messina F. and Piaserico S. in the JEADV.(1) This is the first report of COronaVIrus DIsease 2019 (COVID-19) in a psoriatic patient treated with a biologic. Whilst the authors reported an infection that occurred during therapy with an IL-23 inhibitor, we would like to briefly report one that occurred during therapy with an IL-17 inhibitor."],"journal":"J Eur Acad Dermatol Venereol","authors":["Balestri, R","Rech, G","Girardelli, C R"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32358791","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/jdv.16571","keywords":["il17-inhibitor","sars-cov-2; covid-19; psoriasis","ixekizumab"],"topics":["Case Report"],"weight":1,"_version_":1666138495318491137,"score":187.73474},{"pmid":32479659,"title":"Bullous skin disease patients in a high-epidemic COVID-19 area, Bergamo, Italy.","text":["Bullous skin disease patients in a high-epidemic COVID-19 area, Bergamo, Italy.","Bullous pemphigoid (BP) and pemphigus vulgaris (PV) are blistering disorders associated with barrier disruption, immune dysregulation and use of immunosuppressing systemic therapy. Patients with BP and PV have higher potential risk factors for infections secondary to skin alterations, comorbidity and chronic treatment with immunosuppressing agents.","Br J Dermatol","Carugno, A","Sena, P","Raponi, F","Robustelli Test, E","Vezzoli, P","32479659"],"abstract":["Bullous pemphigoid (BP) and pemphigus vulgaris (PV) are blistering disorders associated with barrier disruption, immune dysregulation and use of immunosuppressing systemic therapy. Patients with BP and PV have higher potential risk factors for infections secondary to skin alterations, comorbidity and chronic treatment with immunosuppressing agents."],"journal":"Br J Dermatol","authors":["Carugno, A","Sena, P","Raponi, F","Robustelli Test, E","Vezzoli, P"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32479659","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/bjd.19266","locations":["Bergamo","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1668437835190894592,"score":170.52237},{"pmid":32458530,"title":"Immunosuppressive and immunomodulator therapy for rare or uncommon skin disorders in pandemic days.","text":["Immunosuppressive and immunomodulator therapy for rare or uncommon skin disorders in pandemic days.","Immunosuppressive and immunomodulatory therapies are important in dermatology, but indications are influenced by SARS-CoV-2. We will focus on are skin disorders such as autoimmune connective tissue disorders, neutrophilic dermatoses and vasculitis. Immunomodulators such as colchicine and antimalarials can easily be preferred taking their beneficial effects on Covid-19 into consideration and also given their wide spectrum of action. Among the conventional therapies, methotrexate, azathioprine and mycophenolate mofetil increase the risk of infection, and thus their use is recommended only when necessary and at low doses. On the other hand, use of cyclosporine is also not recommended as it increases the risk of hypertension, which is susceptible to Covid-19. Anti-TNF agents from among the biological therapies appear to be slightly risky in terms of susceptibility to infection. However, there are ongoing studies which suggest that some biological treatments may reduce cytokine storm impeding the Covid-19 progression as a result, in spite of their susceptibilities to Covid-19. Patients, who will be started on immunosuppressive therapy, should be tested for Covid-19 prior to the therapy, and in the event that Covid-19 is suspected, the therapy should be discontinued. This article is protected by copyright. All rights reserved.","Dermatol Ther","Karadag, Ayse Serap","Aslan Kayiran, Melek","Lotti, Torello","Wollina, Uwe","32458530"],"abstract":["Immunosuppressive and immunomodulatory therapies are important in dermatology, but indications are influenced by SARS-CoV-2. We will focus on are skin disorders such as autoimmune connective tissue disorders, neutrophilic dermatoses and vasculitis. Immunomodulators such as colchicine and antimalarials can easily be preferred taking their beneficial effects on Covid-19 into consideration and also given their wide spectrum of action. Among the conventional therapies, methotrexate, azathioprine and mycophenolate mofetil increase the risk of infection, and thus their use is recommended only when necessary and at low doses. On the other hand, use of cyclosporine is also not recommended as it increases the risk of hypertension, which is susceptible to Covid-19. Anti-TNF agents from among the biological therapies appear to be slightly risky in terms of susceptibility to infection. However, there are ongoing studies which suggest that some biological treatments may reduce cytokine storm impeding the Covid-19 progression as a result, in spite of their susceptibilities to Covid-19. Patients, who will be started on immunosuppressive therapy, should be tested for Covid-19 prior to the therapy, and in the event that Covid-19 is suspected, the therapy should be discontinued. This article is protected by copyright. All rights reserved."],"journal":"Dermatol Ther","authors":["Karadag, Ayse Serap","Aslan Kayiran, Melek","Lotti, Torello","Wollina, Uwe"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32458530","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/dth.13686","keywords":["covid-19","immunomodulatory drugs","immunosuppressive drugs","rare skin diseases"],"topics":["Treatment"],"weight":1,"_version_":1668141322645536769,"score":161.17397}]}